Oncolytic Adenovirus H101 With Nivolumab for Refractory Advanced Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study
ESMO Open 2024 Feb 01;9(2)102239, L Yi, Z Ning, L Xu, Y Shen, X Zhu, W Yu, J Xie, Z MengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.